Angioedema - Pipeline Review, H1 2012
Summary
Global Markets Direct’s, 'Angioedema - Pipeline Review, H1 2012', provides an overview of the Angioedema therapeutic pipeline. This report provides information on the therapeutic development for Angioedema, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Angioedema. 'Angioedema - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for Angioedema.
- A review of the Angioedema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Angioedema pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Angioedema.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Angioedema pipeline depth and focus of Angioedema therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
|
- Introduction
- Global Markets Direct Report Coverage
- Angioedema Overview
- Therapeutics Development
- An Overview of Pipeline Products for Angioedema
- Angioedema Therapeutics under Development by Companies
- Angioedema Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Pre-Clinical Stage Products
- Comparative Analysis
- Angioedema Therapeutics - Products under Development by Companies
- Angioedema Therapeutics - Products under Investigation by Universities/Institutes
- Companies Involved in Angioedema Therapeutics Development
- Pharming Group N.V.
- Dyax Corp.
- ViroPharma Incorporated
- BioCryst Pharmaceuticals, Inc.
- Angioedema - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- DX-88 - Drug Profile
- Rhucin - Drug Profile
- Cinryze - Drug Profile
- Cinryze - Drug Profile
- Ecallantide - Drug Profile
- Icatibant - Drug Profile
- Cinryze + rHuPH20 - Drug Profile
- BCX4161 - Drug Profile
- Angioedema Therapeutics - Drug Profile Updates
- Angioedema Therapeutics - Dormant Products
- Angioedema - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Angioedema, H1 2012
- Products under Development for Angioedema - Comparative Analysis, H1 2012
- Number of Products under Development by Companies, H1 2012
- Number of Products under Investigation by Universities/Institutes, H1 2012
- Comparative Analysis by Late Stage Development, H1 2012
- Comparative Analysis by Mid Clinical Stage Development, H1 2012
- Comparative Analysis by Early Clinical Stage Development, H1 2012
- Comparative Analysis by Pre-Clinical Stage Development, H1 2012
- Products under Development by Companies, H1 2012
- Products under Investigation by Universities/Institutes, H1 2012
- Pharming Group N.V., H1 2012
- Dyax Corp., H1 2012
- ViroPharma Incorporated, H1 2012
- BioCryst Pharmaceuticals, Inc., H1 2012
- Assessment by Monotherapy Products, H1 2012
- Assessment by Combination Products, H1 2012
- Assessment by Stage and Route of Administration, H1 2012
- Assessment by Molecule Type, H1 2012
- Angioedema Therapeutics - Drug Profile Updates
- Angioedema Therapeutics - Dormant Products
- List of Figures
- Number of Products under Development for Angioedema, H1 2012
- Products under Development for Angioedema - Comparative Analysis, H1 2012
- Products under Development by Companies, H1 2012
- Products under Investigation by Universities/Institutes, H1 2012
- Late Stage Products, H1 2012
- Mid Clinical Stage Products, H1 2012
- Early Clinical Stage Products, H1 2012
- Pre-Clinical Stage Products, H1 2012
- Assessment by Monotherapy Products, H1 2012
- Assessment by Combination Products, H1 2012
- Assessment by Route of Administration, H1 2012
- Assessment by Stage and Route of Administration, H1 2012
- Assessment by Molecule Type, H1 2012
- Assessment by Stage and Molecule Type, H1 2012
Share this report
Other tasks Related Markets Drug Discovery Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
